ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » Pediatric Rheumatology - Clinical and Therapeutic Aspects I: Juvenile Idiopathic Arthritis

Meeting: 2013 ACR/ARHP Annual Meeting

Abstract Number: 268
Inflammatory Bowel Disease In Juvenile Idiopathic Arthritis Patients Upon Biologics
Abstract Number: 269
Marked Improvement In Patient Reported Outcomes Of Children With Active Systemic Juvenile Idiopathic Arthritis With Canakinumab Treatment – Results Of The Phase III Program
Abstract Number: 270
Canakinumab In The Treatment Of Systemic Juvenile Idiopathic Arthritis: Results From a 12-Week Pooled Post-Hoc Analysis For Efficacy
Abstract Number: 271
Baseline Characteristics Of Patients With Active Systemic JIA On Canakinumab Therapy Successfully Discontinuing Corticosteroids: Secondary Analyses From A Pivotal PHASE 3 Study
Abstract Number: 272
Predictive Markers Of Joint Damages Of Children With Systemic-Onset Juvenile Idiopathic Arthritis In Long-Term Course Of Treatment With Tocilizumab
Abstract Number: 273
Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk In Patients With Systemic Juvenile Idiopathic Arthritis
Abstract Number: 274
Reported Macrophage Activation Syndrome In Patients With Systemic-Onset Juvenile Idiopathic Arthritis Treated With Tocilizumab
Abstract Number: 275
Changes In Serum IL-18 Level In Systemic Juvenile Idiopathic Arthritis Patients Who Attained Drug-Free Remission By Tocilizumab
Abstract Number: 276
Assessment Of Radiographic Progression In Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2-Year Results From The Tender Trial
Abstract Number: 277
Childhood Arthritis and Rheumatology Research Alliance (CARRA) Standardized Consensus Treatment Plans for New Onset Polyarticular Juvenile Idiopathic Arthritis
Abstract Number: 278
Results Of a 24 Month Extension Study In Patients Who Participated In The Trial Of Early Aggressive Therapy In Polyarticular Juvenile Idiopathic Arthritis
Abstract Number: 279
Safety and Effectiveness Of Adalimumab In Children With Polyarticular Juvenile Idiopathic Arthritis Aged 2 To <4 Years Or ≥4 Years Weighing <15 Kg
Abstract Number: 280
Long-Term Safety and Efficacy Of Etanercept In Paediatric Subjects With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Or Psoriatic Arthritis
Abstract Number: 281
GO-Kids Imaging Substudy: MRI Treatment Response To 30 Mg/m2 4-Weekly Subcutaneous  injections Of Golimumab In Children With Polyarticular JIA – Preliminary Results Of The Open Label Portion
Abstract Number: 282
Rates Of Flare-Free Survival In Juvenile Idiopathic Arthritis When Tapering Individual Components Of Tumor Necrosis Factor Inhibitor and Methotrexate Combination Therapy
Abstract Number: 283
Efficacy Of Biologic Treatments In Juvenile Idiopathic Arthritis With a Polyarticular Course: An Indirect Comparison
Abstract Number: 284
What Is the Relative Priority of the ACR Pediatric Core Set Measures for Youth With Juvenile Idiopathic Arthritis and Their Parents?
Abstract Number: 285
Juvenile Idiopathic Arthritis Patients Demonstrate Alterations In HDL Functionality Without Accelerated Subclinical Atherosclerosis
Abstract Number: 286
Cardiovascular Risk In Adults With Juvenile Idiopathic Arthritis
Abstract Number: 287
Long-Term Evaluation Of Cardiac Function In Juvenile Idiopathic Arthritis Under Anti-Tumor Necrosis Factor Therapy
Abstract Number: 288
MRI Findings In Juvenile Spondyloarthopathy and Effects Of Treatment On Subsequent MRI
Abstract Number: 289
Development and Validation Of The Cutoff Values For Disease Activity States Of The Three-Item Version Of The Juvenile Arthritis Disease Activity Score
Abstract Number: 290
Children With JIA Show Distinct Patterns Of Improvement In Their Health-Related Quality Of Life During The First Year On Treatment: Growth Mixture Modeling Of a Prospective Cohort Of Newly Diagnosed Patients
Abstract Number: 292
Body Surface Area-Based Dosing Approach Produced Comparable Golimumab Exposure Across Different Age Ranges After Subcutaneous Administration Of Golimumab In Pediatric Patients With Juvenile Idiopathic Arthritis
Abstract Number: 293
The Efficacy Of Etanercept In Patients With Juvenile Idiopathic Arthritis With Inadequate Response To Infliximab As a First TNF Inhibitor
Abstract Number: 294
Physical Activity In Children With Juvenile Idiopathic Arthritis (JIA): The LEAP (Linking Exercise, Activity and Pathophysiology in Childhood Arthritis) Study
Abstract Number: 295
Uveitis In The Nordic Juvenile Idiopathic Arthritis Cohort; High Incidence, Frequent Complications, and Gender Associated Risk Factors
Abstract Number: 296
Declines In Levels Of Disease Activity and Physical Disability In Children With Juvenile Idiopathic Arthritis Seen In Standard Clinical Care Over The Last 25 Years
Abstract Number: 297
Plasma Nicotinamide Phosphoribosyltransferase Correlates With Markers Of Inflammation and May Predict Early Therapeutic Response To Low-Dose Methotrexate In Juvenile Idiopathic Arthritis
Abstract Number: 298
Preliminary Prospective Study Of Ultrasonography In Patients With Juvenile Idiopathic Arthritis In Clinical Remission: Subclinical Synovitis May Predict Flare?
Abstract Number: 299
Phenotypic Cluster Analysis Of Juvenile Idiopathic Arthritis: Relationship To International Leagues Of Associations For Rheumatology Classification Criteria

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified ­­­presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2023 American College of Rheumatology